Results 151 to 160 of about 5,441,121 (300)

High on Life? Medical Marijuana Laws and Suicide [PDF]

Using state-level data for the period 1990 through 2007, we estimate the effect of legalizing medical marijuana on suicide rates. Our results suggest that the passage of a medical marijuana law is associated with an almost 5 percent reduction in the ...
Anderson, D. Mark, Rees, Daniel I., Sabia, Joseph J.   +2 more
core  

UK Medical Cannabis Registry: Assessment of clinical outcomes in patients with insomnia

Brain and Behavior
Introduction The primary aim of this study was to assess changes in sleep‐specific health‐related quality of life (HRQoL) for those prescribed cannabis‐based medicinal products (CBMPs) for insomnia.
Kavyesh Vivek, Zekiye Karagozlu, Simon Erridge, Carl Holvey, Ross Coomber, James J. Rucker, Mark W. Weatherall, Mikael H Sodergren   +7 more
doaj   +1 more source

Detecting cannabis use reduction through biochemical verification of urinary cannabinoids: An aggregated analysis of cannabis use disorder treatment trials examining average reductions and individual cut‐points

Addiction, EarlyView.
Abstract Background and aims Currently, there is no data‐driven cannabis reduction metric using biochemical verification, which represents a significant gap in cannabis harm reduction research, treatment and policy. Using aggregated data from 7 cannabis use disorder treatment trials, the aims of this analysis were to 1) determine if decreases in self ...
Erin A. McClure, Brian Neelon, Rachel L. Tomko, Ashley Dowd, Kevin M. Gray, Aimee L. McRae‐Clark, Nathaniel Baker   +6 more
wiley   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source

Medical cannabis in the management of musculoskeletal pain: a systematic review of clinical trials

Cannabinoids not only act through classical cannabinoid receptors but also influence a wide range of physiological processes via numerous cellular signaling pathways.
Laura Piejko, Przemysław Płatek
core   +1 more source

Cannabis products: medical use

Revista da Associação Médica Brasileira, 2023
César Eduardo Fernandes, José Eduardo Lutaif Dolci, Leonardo Sobral Navarro, Marcelo Allevato, Clóvis Francisco Constantino, Rodrigo Pastor Alves Pereira, Carlos Roberto de Mello Rieder, Flávia Torino, Wanderley Marques Bernardo, Antônio Geraldo da Silva   +9 more
openaire   +3 more sources

Commentary on Borodovsky et al.: Enhancing research on THC quantification—Consumer awareness through accurate labelling

Addiction, Volume 120, Issue 4, Page 686-687, April 2025.
Rachel Lees Thorne, Tom P. Freeman
wiley   +1 more source

Associations of cannabis use, tobacco use and co‐use with brain volume: A systematic review and meta‐analysis

Addiction, EarlyView.
Abstract Background and aims Cannabis is the most widely used illicit drug worldwide and is often co‐used with tobacco, the leading cause of preventable death. Although cannabis and tobacco have distinct neurobiological actions, their associations with brain volumes are unclear.
Katherine Sawyer, Tom P. Freeman, Martine Skumlien, Esther Walton, Thomas Lancaster, Jorien L. Treur, Valentina Lorenzetti, Anna K. M. Blackwell, Chloe Burke, Richie J. Carr, Constantinos Constantinides, Maisie Cox, Sarah Dance, Shadi Daryan, Sorcha Hamilton, Tom Jenkins, Gemma M. J. Taylor   +16 more
wiley   +1 more source

Medical cannabis Q&A [PDF]

Canadian Pharmacists Journal / Revue des Pharmaciens du Canada, 2017
openaire   +2 more sources

Proportions and correlates of high‐risk cannabis use in Australia—A cross‐sectional analysis of the 2022–2023 National Drug Strategy Household Survey

Addiction, EarlyView.
Abstract Background and aim Cannabis use is prevalent in Australia, however, limited research has explored the levels of high‐risk cannabis use within nationally representative samples. This study aimed to address this gap by examining the proportion of individuals meeting criteria for high‐risk cannabis use and identifying its correlates in a ...
Janni Leung, Daniel Stjepanović, Gary Chung Kai Chan, Wayne Denis Hall, Danielle Dawson   +4 more
wiley   +1 more source